Author

@Gantosj Gantosj

Named retail analyst championing a concentrated micro-cap lithium-DLE and biotech basket

Original bottom-up fundamental research and milestone tracki

trader score
-2.45
hit rate
30%
mean α
-2.58%
signals 14d
38

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.

Their picks, scored

Across their last 20 scored bets: 30% hit rate, -2.58% mean alpha, trader score -2.45. Their last-14d mentions, direction-adjusted, have moved -21.9% since posting (mean over 15 mentions with price data).

Recent signals15receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-10-16LIB.V@Gantosj+0.85Models up to $400M annual revenue from a 20,000-tpa commercial pipeline by 2028-2029.·
2026-10-16VLTLF@Gantosj+0.85Models up to $400M annual revenue from a 20,000-tpa commercial pipeline by 2028-2029.-16.7%
2026-10-16LIB.V@Gantosj+0.65Reports a 2028 demand pipeline spanning signed offtakes, MOUs, negotiations, and an RFP.·
2026-10-16VLTLF@Gantosj+0.65Reports a 2028 demand pipeline spanning signed offtakes, MOUs, negotiations, and an RFP.-16.7%
2026-10-16LIB.V@Gantosj+0.45Reports extension of a $95M financing arrangement through November 14, 2026.·
2026-10-16VLTLF@Gantosj+0.45Reports extension of a $95M financing arrangement through November 14, 2026.-16.7%
2026-10-16LIB.V@Gantosj+0.50Reports seven prospective customers and potential 2028 demand of 9,100 tonnes annually.·
2026-10-16VLTLF@Gantosj+0.50Reports seven prospective customers and potential 2028 demand of 9,100 tonnes annually.-16.7%
2026-10-16LIB.V@Gantosj+0.55Reports potential 2028 demand of 9,100 tonnes annually, including 600 under an offtake.·
2026-10-16VLTLF@Gantosj+0.55Reports potential 2028 demand of 9,100 tonnes annually, including 600 under an offtake.-16.7%
2026-10-16LIB.V@Gantosj+0.35LibertyStream says its Texas lithium carbonate is under evaluation by prospective customers.·
2026-10-16VLTLF@Gantosj+0.35LibertyStream says its Texas lithium carbonate is under evaluation by prospective customers.-16.7%
2026-10-15EPRX@Gantosj+0.35Eupraxia's 60-patient Phase 2b interim analysis remains on track for December 2026.+1.5%
2026-10-15EPRX@Gantosj+0.55Eupraxia reached its RESOLVE enrollment target with no sample-size adjustment required.+1.5%
2026-10-15CNVI.V@Gantosj+0.30Conavi technology earned an oral presentation slot at the TCT26 conference.·

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.